Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Dave, Bhuvanesh ^a   Landis, Melissa D ^a   Dobrolecki, Lacey E ^a   Wu, Meng Fen ^b   Zhang, Xiaomei ^b   Westbrook, Thomas F ^b   Hilsenbeck, Susan G ^b   Liu, Dan ^b   Lewis, Michael T ^b   Tweardy, David J ^b   Chang, Jenny C ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; C 188; CD24 ANTIGEN; DOCETAXEL; HERMES ANTIGEN; SHORT HAIRPIN RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESISTANCE; DRUG SELECTIVITY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TUMOR CELL; TUMOR INITIATING CELL; TUMOR XENOGRAFT;

ADIPOSE TISSUE; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MICE; MICE, SCID; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; SMALL MOLECULE LIBRARIES; STAT3 TRANSCRIPTION FACTOR; TAXOIDS; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84864673390     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030207     Document Type: Article

References (22)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF, ((2003)) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983-3988.
2. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, et al. ((2009)) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 106:13820-13825.
3. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS, ((2003)) Stem cells in normal breast development and breast cancer. Cell Prolif 36 Suppl 1: 59-72.
4. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, et al. ((2008)) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100:672-679.
5. Redell MS, Tweardy DJ, ((2005)) Targeting transcription factors for cancer therapy. Curr Pharm Des 11:2873-2887.
6. Turkson J, Jove R, ((2000)) STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19:6613-6626.
7. Chen Z, Han ZC, ((2008)) STAT3: a critical transcription activator in angiogenesis. Med Res Rev 28:185-200.
8. Xu X, Kasembeli MM, Jiang X, Tweardy BJ, Tweardy DJ, ((2009)) Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS One 4:e4783.
9. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, et al. ((2007)) Molecular definition of breast tumor heterogeneity. Cancer Cell 11:259-273.
10. Kakarala M, Brenner DE, Korkaya H, Cheng C, Tazi K, et al. ((2010)) Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat 122:777-785.
11. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, et al. ((2010)) CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 120:485-497.
12. Huang Y, Qiu J, Dong S, Redell MS, Poli V, et al. ((2007)) Stat3 isoforms, alpha and beta, demonstrate distinct intracellular dynamics with prolonged nuclear retention of Stat3beta mapping to its unique C-terminal end. J Biol Chem 282:34958-34967.
13. Sharp ZD, Mancini MG, Hinojos CA, Dai F, Berno V, et al. ((2006)) Estrogen-receptor-alpha exchange and chromatin dynamics are ligand- and domain-dependent. J Cell Sci 119:4101-4116.
14. Garcia R, Bowman TL, Niu G, Yu H, Minton S, et al. ((2001)) Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20:2499-2513.
15. Ramana CV, Chatterjee-Kishore M, Nguyen H, Stark GR, ((2000)) Complex roles of Stat1 in regulating gene expression. Oncogene 19:2619-2627.
16. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, et al. ((2007)) Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A 104:7391-7396.
17. Jing N, Li Y, Xiong W, Sha W, Jing L, et al. ((2004)) G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res 64:6603-6609.
18. Becker S, Groner B, Muller CW, ((1998)) Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 394:145-151.
19. Villalva C, Martin-Lannerée S, Cortes U, Dkhissi F, Wager M, et al. ((2010)) STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: A potential for targeted therapy? International Journal of Cancer: n/a-n/a.
20. Wei J, Barr J, Kong LY, Wang Y, Wu A, et al. ((2010)) Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther 9:67-78.
21. Kim DJ, Tremblay ML, Digiovanni J, ((2010)) Protein tyrosine phosphatases, TC-PTP, SHP1, and SHP2, cooperate in rapid dephosphorylation of Stat3 in keratinocytes following UVB irradiation. PLoS One 5:e10290.
22. Dontu G, Liu S, Wicha MS, ((2005)) Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev 1:207-213.